EN | TR
E-ISSN: 2651-2661 ISSN: 2651-2653
Secukinumab experience in a case of ankylosing spondylitis complicated with renal failure
PDF
Cite
Share
Request
Case Report
VOLUME: 12 ISSUE: 1
P: 27-29
April 2020

Secukinumab experience in a case of ankylosing spondylitis complicated with renal failure

J Turk Soc Rheumatol 2020;12(1):27-29
DOI: 10.4274/raed.galenos.2019.62207
Firdevs Ulutaş
Uğur Karasu
Serdar Kaymaz
Veli Çobankara
1. Pamukkale Üniversitesi Tıp Fakültesi, Romatoloji Bilim Dalı, Denizli, Türkiye
No information available.
No information available
Received Date: 16.12.2019
Accepted Date: 30.12.2019
Publish Date: 06.05.2020
PDF
Cite
Share
Request

ABSTRACT

Ankylosing spondylitis is a rheumatologic disease characterized with inflammatory back pain, radiographic signs of sacroiliitis, enthesopathy and extra-articular findings (uveitis, psoriasis, inflammatory bowel disease). Non-steroidal anti-inflammatory drugs, TNF inhibitors and anti-IL17 agents are used in the treatment of ankylosing spondylitis. Secukinumab is a selective anti-interleukin 17A Ig G1 kappa monoclonal antibody, used in the treatment of ankylosing spondylitis, psoriatic arthritis, psoriasis. In this paper, we report a case of ankylosing spondylitis complicated by end-stage renal failure, accompanied by retroperitoneal fibrosis, which successfully managed with secukinumab. The patient’s information and results were shared after obtaining patient approval and consent.

References

1Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. New England Journal of Medicine 2016;374:2563-74.
2Hueber W, Patel D, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Science Translational Medicine 2010;2:52-3.
3Torgutalp M, Poddubnyy D. IL-17 inhibition in axial pondyloarthritis: current and future perspectives. Expert Opinion Biological Therapy 2019;19:631-41.
4Asseement report EMA(CHMP Cosentyx (secukinumab). European Medicines Agency 2015.
5Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatology 2019;71:1599-613.
6Abd El Hafezz S, Hegazy R, Naga Y, Wahdan I, Sallam S, et al. Non-steroidal anti-İnflammatory drugs among chronic kidney disease patients; an epidemiological study. J Egypt Public Health Association 2019;94:8-9.
7Wenling Ye, Jing Zhuang, Yang Yu, Hang Li, Xiaomei Leng, Jun Qian, et al. Gender anda chronic kidney disease in ankylosing spondylitis:single-centre retrospectively study. BMC Nefrology 2019;20:457.
8Babino G, Fulgione E, Giorgio CM, Agozzino M, Alfano R, Argenziano G. Efficacy and safety of secukinumab in a psoriatic patient affected by comorbid metabolic disorders. Dermatological Therapy 2019;32:128-30.
9Shibata T, Muto J, Takama H, Yanagishita T, Ito T, Watanabe D. Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab. Journal of Dermatology 2019;46:119-20.
10Afeltra A, Vespasiani U, Rabitti C, Amoroso A, Caricato M, Vadacca M, et al. Retroperitoneal Fibrosis and Ankylosing Spondylitis; Which Links? Seminars in Arthritis and Rheumatism 2005;35:43-8.
11Solomon SD, Maurer KH. The association of retroperitoneal fibrosis and ankylosing spondylitis. J Rheumatol 1985;12:818-19.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House